VERWENDUNG VON LAMBDA-INTERFERONEN BEI DER BEHANDLUNG EINER MIT FETTLEIBIGKEIT IN ZUSAMMENHANG STEHENDEN STÖRUNG, VON ATHEROSKLEROSE ODER EINER GERINNUNGSSTÖRUNG
European patent · EP3375452 · In force
Register entry
- Publication number
- EP3375452
- Application number
- EP17161461
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Mar 16, 2017
- Published
- Sep 19, 2018
- Granted
- Jan 8, 2025
- Protection ends at the latest
- Mar 15, 2037
- Next annual fee due
- Mar 31, 2027
- IPC classes
- A61K 38/21 (2006.01)A61P 3/04 (2006.01)A61P 9/10 (2006.01)A61P 7/02 (2006.01)
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Apr 23, 2026
Change
Published in Swissreg on 23.04.2026
- Nov 19, 2025
Change
Published in Swissreg on 19.11.2025
- Apr 1, 2025
Change
Published in Swissreg on 01.04.2025
- Mar 7, 2025
Agent entered
- Representative
- VALIPAT, c/o BOVARD LTD, Optingenstrasse 16, 3013 Bern
Published in Swissreg on 07.03.2025
- Jan 8, 2025
Granted
- Specification status
- Non-published patent application → Granted patent
- Status of protective title
- Initiated → Active
Published in Swissreg on 08.01.2025
Parties
Holder
Andreakos, Evangelos
15451 Athens, GR
Salagianni, Maria
17563 Athens, GR
Biomedical Research Foundation of the Academy of Athens
Soranou Efesiou 4, 115 27 Athens, GR
Inventor
Andreakos, Evangelos
15451 Athens, GR
Salagianni, Maria
17563 Athens, GR
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.